StockData
GoodRx Holdings, Inc. logo

GoodRx Holdings, Inc. (GDRX) stock

GDRXNasdaqServices-Computer Processing & Data PreparationFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 11/3037% below fair value
$3.47−0.04 (-1.14%)

Close on Nov 17, 2026Market cap $1.18BP/E 86.8Yield –

GoodRx ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

GoodRx's ebitda for the twelve months ending Jun 30, 2026 was $163.58M, down 1.5% year over year. For fiscal 2025 it was $172.71M, up 27.6% from the year before. The highest annual figure on record is $172.71M in fiscal 2025.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025$172.71M+27.6%
FY2024Dec 31, 2024$135.38M+67.8%
FY2023Dec 31, 2023$80.66M+44.3%
FY2022Dec 31, 2022$55.92M+16.6%
FY2021Dec 31, 2021$47.95M–
FY2020Dec 31, 2020-$257.29M-267.9%
FY2019Dec 31, 2019$153.25M+76.0%
FY2018Dec 31, 2018$87.06M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$45.90M-1.4%
Q1 FY2026Mar 31, 2026$35.80M-19.2%
Q4 FY2025Dec 31, 2025$45.83M+22.9%
Q3 FY2025Sep 30, 2025$36.05M-5.0%
Q2 FY2025Jun 30, 2025$46.54M+26.3%
Q1 FY2025Mar 31, 2025$44.29M+89.9%
Q4 FY2024Dec 31, 2024$37.28M+47.2%
Q3 FY2024Sep 30, 2024$37.94M–
Q2 FY2024Jun 30, 2024$36.84M+7.1%
Q1 FY2024Mar 31, 2024$23.32M-11.1%
Q4 FY2023Dec 31, 2023$25.32M+46.6%
Q3 FY2023Sep 30, 2023-$5.31M–
Q2 FY2023Jun 30, 2023$34.41M+271.1%
Q1 FY2023Mar 31, 2023$26.24M-15.7%
Q4 FY2022Dec 31, 2022$17.27M-22.9%
Q3 FY2022Sep 30, 2022-$1.76M-110.3%
Q2 FY2022Jun 30, 2022$9.27M+15.6%
Q1 FY2022Mar 31, 2022$31.13M+8476.9%
Q4 FY2021Dec 31, 2021$22.40M–
Q3 FY2021Sep 30, 2021$17.16M–
Q2 FY2021Jun 30, 2021$8.02M-82.7%
Q1 FY2021Mar 31, 2021$363.00K-99.2%
Q4 FY2020Dec 31, 2020-$295.04M-837.9%
Q3 FY2020Sep 30, 2020-$56.53M-236.4%
Q2 FY2020Jun 30, 2020$46.26M–
Q1 FY2020Mar 31, 2020$48.02M–
Q4 FY2019Dec 31, 2019$39.99M–
Q3 FY2019Sep 30, 2019$41.45M–

More GoodRx figures

See a number that looks wrong?